Guardian Liberty VoiceHemophilia B Long-Acting Treatment Approved in CanadaGuardian Liberty VoiceHemophilia B It was announced today that ALPROLIX, the first long-acting coagulation factor treatment for hemophilia B, has been approved by Health Canada. ALPROLIX use is for controlling and preventing bleeding occurrences in adults and adolescents.Biogen Idec CEO talks pipeline, keys to growthCNBC.comWhy Biogen Idec (BIIB) Is Down TodayTheStreet.comCanada Approves Hemophilia B Drug AlprolixThe AlmagestNorthern Voices Online -News & Observer -Reutersall 37 news articles …read more
Via: Google USA
Hemophilia B Long-Acting Treatment Approved in Canada - Guardian Liberty Voice
Real Estate of Cebu
